Visgeneer (4197) Fair Value & Analysis
Healthcare · TW · Market cap 275M TWD (≈ $8.7M) · ISIN TW0004197009
What is Visgeneer really worth?
A solid business, but trading 199% above our fair value of 2.89 TWD.
As of Sep 6, 2026, the fair value of Visgeneer is 2.89 TWD per share against a price of 8.63 TWD, so the fair value sits 67% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
Fair value as of: Sep 6, 2026
From 21 valuation models · updated today
Share price +1.4% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (3.33 TWD). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 6, 2026.
How to read this chart
60‑month range 8.15 TWD – 19.00 TWD · fair‑value band 2.02 TWD – 3.33 TWD · the 8.63 TWD price screens above the 2.89 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 6, 2026.
Analysis
Visgeneer (4197) currently trades at 8.63 TWD, while our model-based Fair Value estimate is 2.89 TWD, implying the stock looks roughly 198.6% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bull case: the Asset-Based group reads highest at a median of 4.42 TWD per share, and 0 of the 21 models we run sit above the 8.63 TWD price. Bear case: the Earnings-Based group reads lowest at 1.44 TWD, and 21 of the 21 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Visgeneer generated revenue of 179M TWD at a net margin of 2.9%. Revenue grew 27.7% year over year. It earns a return on equity of 2.7%. Net debt stands at 35.4M TWD. Fundamentals as of Sep 6, 2026
Our scenario range runs from 2.02 TWD (bear case) to 3.33 TWD (bull case); at 8.63 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 62% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −67%, 4197 screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 0.1160 TWD per share, which is 4.0 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 21 models by family
Widest divergence: Asset-Based (4.42 TWD) versus Earnings-Based (1.44 TWD). Highest evidence: FCF DCF (80).
Notify me when 4197 reaches fair value
Put 4197 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 6, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Visgeneer Inc. provides health solutions in the fields of medical device, cosmetics and skin care, Zeaxanthin, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems.
Full company description
Visgeneer Inc. provides health solutions in the fields of medical device, cosmetics and skin care, Zeaxanthin, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; face cream, night cream, day cream, wrinkle cream, repairing cream, whitening cream, exfoliating cream, toner, and lotions; functional essences; body lotion and spa clay mask; physical blocker, chemical blocker, and comprehensive sun protection; face wash, wash cream, cleaning cleansing mousse, cleaning cleansing gel, shampoo, and body wash; hand cream, knee cream, foot mask, hand mask, and glucosamine cream; anti-acne cream, female private cleaning lotion, skin care, skin capsules, and hair capsules; and customized skin care products. In addition, the company offers eBmonitor Blood Monitoring System, CoreSence Skincare, BOWIL Skincare, angera, and ZeaSight EU Patent Zeaxanthin. Visgeneer Inc. was founded in 2005 and is based in Hsinchu City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Visgeneer reported revenue of 179M TWD in FY2025 versus 165M TWD in FY2021, a compound +2.0%/yr. Reported net income was 5.2M TWD in FY2025, compounding +59.0%/yr from FY2021.
4197 screens 199% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 627 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Sep 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| BeOne Medicines AG 688235 | ¥271.00 | ¥47.36 | −83% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BioNTech SE BNTX | $103.76 | $45.70 | −56% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare Visgeneer with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Visgeneer (4197) overvalued or undervalued?
What is the fair value of 4197?
What is the quality score of 4197?
What is the price target for Visgeneer (4197)?
What is the Visgeneer stock forecast for 2026?
What is the revenue of Visgeneer (4197)?
What is the net profit margin of 4197?
Does Visgeneer pay a dividend?
Watch Visgeneer in the live analysis
One click puts Visgeneer on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.